Parmax Pharma [PARMAX] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison

Parmax Pharma Ltd.

BSE
Loading...

Sun Pharma Advanced Research Company Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Parmax Pharma Ltd. wins in 12 metrics, Sun Pharma Advanced Research Company Ltd. wins in 5 metrics, with 0 ties. Parmax Pharma Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Parmax Pharma Ltd. Sun Pharma Advanced Research Company Ltd. Better
P/E Ratio (TTM) -5.63 -13.65 Parmax Pharma Ltd.
Price-to-Book Ratio -2.43 -13.55 Parmax Pharma Ltd.
Debt-to-Equity Ratio -2.38 -1.21 Sun Pharma Advanced Research Company Ltd.
PEG Ratio -0.06 -11.15 Parmax Pharma Ltd.
EV/EBITDA 109.78 -22.27 Parmax Pharma Ltd.
Profit Margin (TTM) 15.84% -53.22% Parmax Pharma Ltd.
Operating Margin (TTM) -6.82% -700.71% Parmax Pharma Ltd.
Return on Equity 105.30% 157.88% Sun Pharma Advanced Research Company Ltd.
Return on Assets (TTM) -11.17% -102.08% Parmax Pharma Ltd.
Free Cash Flow (TTM) $-16.59M $-3.71B Parmax Pharma Ltd.
1-Year Return -18.44% 14.56% Sun Pharma Advanced Research Company Ltd.
Price-to-Sales Ratio (TTM) 0.42 87.98 Parmax Pharma Ltd.
Enterprise Value $197.87M $50.87B Sun Pharma Advanced Research Company Ltd.
EV/Revenue Ratio 0.70 95.73 Parmax Pharma Ltd.
Gross Profit Margin (TTM) 28.35% -59.53% Parmax Pharma Ltd.
Revenue per Share (TTM) $75 $2 Parmax Pharma Ltd.
Earnings per Share (Diluted) $-13.55 $-8.25 Sun Pharma Advanced Research Company Ltd.
Beta (Stock Volatility) N/A 0.19 N/A

Parmax Pharma Ltd. vs Sun Pharma Advanced Research Company Ltd. Stock Performance Analysis

Loading Price Chart...

PARMAX
SPARC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Parmax Pharma Ltd.-10.44%37.89%57.11%56.72%48.13%51.69%
Sun Pharma Advanced Research Company Ltd.-0.07%-3.79%52.45%72.49%40.02%57.72%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Parmax Pharma Ltd.-18.44%19.45%-36.21%196.24%196.24%196.24%
Sun Pharma Advanced Research Company Ltd.14.56%13.10%-5.14%-23.02%148.11%-27.03%

Performance & Financial Health Analysis: Parmax Pharma Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricPARMAXSPARC
Market Information
Market Cap i₹117.89M₹46.75B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i3912,401,062
90 Day Avg. Volume i6642,083,443
Last Close₹45.73₹212.82
52 Week Range₹22.60 - ₹53.38₹108.00 - ₹248.75
% from 52W High-14.33%-14.44%
All-Time High₹81.90 (Jun 14, 2021)₹875.00 (Apr 24, 2006)
% from All-Time High-44.16%-75.68%
Growth Metrics
Quarterly Revenue Growth0.71%-0.43%
Quarterly Earnings Growth-0.31%-0.43%
Financial Health
Profit Margin (TTM) i0.16%-0.53%
Operating Margin (TTM) i-0.07%-7.01%
Return on Equity (TTM) i1.05%1.58%
Debt to Equity (MRQ) i-2.38-1.21
Cash & Liquidity
Book Value per Share (MRQ)₹-12.94₹-10.63
Cash per Share (MRQ)N/A₹0.03
Operating Cash Flow (TTM) i₹-20,488,477₹-3,484,287,000
Levered Free Cash Flow (TTM) i₹-20,940,101₹-3,425,094,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Parmax Pharma Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricPARMAX (Apr 24, 2026)SPARC (Apr 22, 2026)
Price Ratios
P/E Ratio (TTM) i-5.63-13.65
Forward P/E iN/A2.60
PEG Ratio i-0.06-11.15
Price to Sales (TTM) i0.4287.98
Price to Book (MRQ) i-2.43-13.55
Market Capitalization
Market Capitalization i₹117.89M₹46.75B
Enterprise Value i₹197.87M₹50.87B
Enterprise Value Metrics
Enterprise to Revenue i0.7095.73
Enterprise to EBITDA i109.78-22.27
Risk & Other Metrics
Beta iN/A0.19
Book Value per Share (MRQ) i₹-12.94₹-10.63

Financial Statements Comparison: Parmax Pharma Ltd. vs Sun Pharma Advanced Research Company Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPARMAX (2025)SPARC (2025)
Revenue/Sales i282.04M717.66M
Cost of Goods Sold i237.36M1.10B
COGS % of Revenue i84.2%153.2%
Gross Profit i44.68M-381.94M
Gross Margin i15.8%-53.2%
Research & Development iN/AN/A
Operating Income (EBIT) i-7.77M-3.34B
Operating Margin i-2.8%-465.5%
EBITDA i1.80M-3.23B
EBITDA Margin i0.6%-450.0%
Pre-Tax Income i-23.95M-3.43B
Pre-Tax Income % of Revenue i-8.5%-477.6%
Income Tax i-3.01M-2.72M
Income Tax % of Revenue i-1.1%-0.4%
Net Income (Profit) i-20.94M-3.43B
Profit Margin i-7.4%-477.3%

Balance Sheet & Liquidity Metrics

MetricPARMAX (2025)SPARC (2025)
Cash & Equivalents i903,27919.64M
Total Current Assets i100.03M261.97M
Total Current Assets % of Revenue i35.5%36.5%
Total Current Liabilities i130.37M3.74B
Total Current Liabilities % of Revenue i46.2%521.5%
Long-Term Debt i77.04M1.07B
Long-Term Debt % of Revenue i27.3%149.0%
Total Shareholders Equity i-19.89M-2.17B
Retained Earnings i-64.40M-23.22B
Retained Earnings % of Revenue i-22.8%-3,235.0%
Property, Plant & Equipment i17.29M178.02M

Cash Flow Statement Comparison

MetricPARMAX (2025)SPARC (2025)
Operating Cash Flow i-20.49M-3.48B
Operating Cash Flow % of Revenue i-7.3%-485.5%
Capital Expenditures i-7.01M-97.45M
Free Cash Flow i-16.59M-3.71B
FCF Margin i-5.9%-516.4%
Debt Repayment iN/A-3.69B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPARMAXSPARC
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i3.74M324.52M
Float Shares iN/A91.32M
% Held by Insiders i64.25%72.96%
% Held by Institutions i0.00%2.56%
% Held by Public i35.75%24.48%

Dividend Analysis & Yield Comparison: Parmax Pharma Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricPARMAXSPARC
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A